vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and FrontView REIT, Inc. (FVR). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $16.5M, roughly 1.1× FrontView REIT, Inc.). CytomX Therapeutics, Inc. runs the higher net margin — -0.8% vs -24.9%, a 24.1% gap on every dollar of revenue.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
CTMX vs FVR — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $16.5M |
| Net Profit | $-154.0K | $-4.1M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | — |
| Net Margin | -0.8% | -24.9% |
| Revenue YoY | -25.7% | — |
| Net Profit YoY | 97.6% | — |
| EPS (diluted) | — | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $16.5M | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | $18.7M | $17.6M | ||
| Q1 25 | $50.9M | $16.2M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $33.4M | $14.5M | ||
| Q2 24 | $25.1M | — | ||
| Q1 24 | $41.5M | — |
| Q4 25 | — | $-4.1M | ||
| Q3 25 | — | $4.0M | ||
| Q2 25 | $-154.0K | $-2.9M | ||
| Q1 25 | $23.5M | $-833.0K | ||
| Q4 24 | $18.9M | — | ||
| Q3 24 | $5.7M | $-2.4M | ||
| Q2 24 | $-6.5M | — | ||
| Q1 24 | $13.8M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -6.9% | — | ||
| Q1 25 | 44.4% | — | ||
| Q4 24 | 46.4% | — | ||
| Q3 24 | 12.3% | — | ||
| Q2 24 | -33.7% | — | ||
| Q1 24 | 28.1% | — |
| Q4 25 | — | -24.9% | ||
| Q3 25 | — | 23.9% | ||
| Q2 25 | -0.8% | -16.5% | ||
| Q1 25 | 46.2% | -5.1% | ||
| Q4 24 | 49.6% | — | ||
| Q3 24 | 17.2% | -16.7% | ||
| Q2 24 | -26.0% | — | ||
| Q1 24 | 33.3% | — |
| Q4 25 | — | $-0.19 | ||
| Q3 25 | — | $0.19 | ||
| Q2 25 | — | $-0.16 | ||
| Q1 25 | — | $-0.06 | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $13.5M |
| Total DebtLower is stronger | — | $314.3M |
| Stockholders' EquityBook value | $119.9M | $391.2M |
| Total Assets | $175.1M | $854.4M |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $13.5M | ||
| Q3 25 | — | $19.6M | ||
| Q2 25 | $49.0M | $8.4M | ||
| Q1 25 | $47.6M | $3.3M | ||
| Q4 24 | $38.1M | — | ||
| Q3 24 | $40.6M | — | ||
| Q2 24 | $43.2M | — | ||
| Q1 24 | $36.2M | — |
| Q4 25 | — | $314.3M | ||
| Q3 25 | — | $307.1M | ||
| Q2 25 | — | $316.9M | ||
| Q1 25 | — | $310.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $391.2M | ||
| Q3 25 | — | $385.2M | ||
| Q2 25 | $119.9M | $369.9M | ||
| Q1 25 | $25.0M | $324.7M | ||
| Q4 24 | $-456.0K | — | ||
| Q3 24 | $-23.5M | $1.0K | ||
| Q2 24 | $-31.2M | — | ||
| Q1 24 | $-31.7M | — |
| Q4 25 | — | $854.4M | ||
| Q3 25 | — | $846.8M | ||
| Q2 25 | $175.1M | $856.5M | ||
| Q1 25 | $98.5M | $860.8M | ||
| Q4 24 | $120.5M | — | ||
| Q3 24 | $139.0M | $1.0K | ||
| Q2 24 | $159.2M | — | ||
| Q1 24 | $184.7M | — |
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.80× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $42.1M |
| Free Cash FlowOCF − Capex | $-15.8M | — |
| FCF MarginFCF / Revenue | -84.6% | — |
| Capex IntensityCapex / Revenue | 0.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $42.1M | ||
| Q3 25 | — | $8.3M | ||
| Q2 25 | $-15.8M | $9.3M | ||
| Q1 25 | $-21.0M | $8.1M | ||
| Q4 24 | $-19.9M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.5M | — | ||
| Q1 24 | $-26.0M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-15.8M | — | ||
| Q1 25 | $-21.2M | — | ||
| Q4 24 | $-20.0M | — | ||
| Q3 24 | $-20.7M | — | ||
| Q2 24 | $-19.6M | — | ||
| Q1 24 | $-26.2M | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -84.6% | — | ||
| Q1 25 | -41.6% | — | ||
| Q4 24 | -52.5% | — | ||
| Q3 24 | -62.1% | — | ||
| Q2 24 | -78.2% | — | ||
| Q1 24 | -63.1% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 0.1% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 0.2% | — | ||
| Q3 24 | 0.1% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 0.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | -0.89× | — | ||
| Q4 24 | -1.05× | — | ||
| Q3 24 | -3.61× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | -1.89× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
FVR
Segment breakdown not available.
